Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED STATES: Bristol Reaches $80 Million Deal to Settle Hepatitis C Claims


Wall Street Journal (01.24.13)

The pharmaceutical company Bristol-Myers Squibb has agreed to pay $80 million to settle cases involving 15 patients who either died or were hospitalized while participating in company-sponsored testing of the experimental hepatitis C drug informally identified as 094. A Bristol spokesperson says there is “an agreement in principle to settle the matters that were in mediation,” but also stated the terms were confidential. The tentative settlement will resolve legal issues the drug maker has been dealing with since halting development of the hepatitis C treatment in August 2012 after one death and several hospitalizations during testing. Drug 094 was the highly anticipated highlight of Bristol’s 2012 $2.5 billion acquisition of Inhibitex, which initially developed the pill.


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in January 29, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.